What the business is, and whether it's a good one at a fair price.
Sells branded prescription pharmaceutical products in India across gynaecology, orthopaedics, dermatology and child-care, with a 40-plus-year track record and over 20 brands ranked in the top 5 of their molecule categories. Revenue is concentrated: the top 10 brands contribute 58-60% of sales and nine of those rank top-5 in their respective categories, while five brands rank #1 in their molecules. Growth comes from medical-representative (MR) productivity rather than field-force expansion — no new MRs are planned — with the portfolio shifting toward semi-chronic and specialty therapies. In June 2026 it acquired an 85% stake in Aequitas Healthcare for Rs 20.8 crore, adding a hospital-channel business that sold to 1,000-plus hospitals and 4,000-plus specialty doctors in FY26 (Rs 53 crore revenue). The biggest cost line is employees at 24.6% of revenue, reflecting the MR-heavy sales model; raw materials are only 5.6% of revenue. Capital returns are a feature of the model — FY26 included a Rs 40 crore buyback at a 44% premium and a 200% dividend (with a 75% special dividend component).
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from JAGSONPAL PHARMACEUTICALS's filed financials and exchange disclosures
JAGSONPAL PHARMACEUTICALS is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol JAGSNPHARM.
Yes. Over the trailing twelve months JAGSONPAL PHARMACEUTICALS reported a net profit of ₹45 Cr on revenue of ₹294 Cr.
Not in the latest reported year — JAGSONPAL PHARMACEUTICALS's dividend payout for FY26 was nil.
Effectively yes. It holds ₹10 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, JAGSONPAL PHARMACEUTICALS ranks 95 of 169 in Pharmaceuticals — cheaper than 44% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session JAGSONPAL PHARMACEUTICALS moves 1.18% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by JAGSONPAL PHARMACEUTICALS appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
